Fig. 6From: The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7The FBP1 inhibitors and SMAD7 inhibitors entering clinical trials. FBP1 fructose-1,6-bisphosphatase, SMAD7 mothers against decapentaplegic homolog 7, T2DM type 2 diabetes mellitus, CD Crohn’s diseaseBack to article page